ArticleCancer causes & control : CCC2010
Genetic variation in sex-steroid receptors and synthesizing enzymes and colorectal cancer risk in women.
Article in Cancer causes & control : CCC, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- CYP24A1 variant modifies the association between use of oestrogen plus progestogen therapy and colorectal cancer risk.British journal of cancer · 2016Pooled it
- Trial
- Prognostic value of fatty acid metabolism-related genes in colorectal cancer and their potential implications for immunotherapy.Frontiers in immunology · 2023Article
- Common variability in oestrogen-related genes and pancreatic ductal adenocarcinoma risk in women.Scientific reports · 2022Article
- Genome-Wide Interaction Analysis of Genetic Variants With Menopausal Hormone Therapy for Colorectal Cancer Risk.Journal of the National Cancer Institute · 2022Article
- No association between germline variation in catechol-O-methyltransferase and colorectal cancer survival in postmenopausal women.Menopause (New York, N.Y.) · 2014Article
- Oestrogen and colorectal cancer: mechanisms and controversies.International journal of colorectal disease · 2013Review
- Common single-nucleotide polymorphisms in the estrogen receptor β promoter are associated with colorectal cancer survival in postmenopausal women.Cancer research · 2013Article
- Genetic variation in insulin pathway genes and distal colorectal adenoma risk.International journal of colorectal disease · 2012Article
- Variation in the CYP19A1 gene and risk of colon and rectal cancer.Cancer causes & control : CCC · 2011Article
- Estrogen and progesterone-related gene variants and colorectal cancer risk in women.BMC medical genetics · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
objectivesSeveral lines of evidence have suggested that female hormones may lower the risk for developing colorectal cancer. However, the mechanisms by which sex hormones affect colorectal cancer development remain unknown. We sought to determine whether the association may be under genetic control by evaluating genetic variation in estrogen receptors (ESR1 and ESR2), progesterone receptor (PGR), aromatase cytochrome 450 enzyme (CYP19A1), and 17 beta-hydroxysteroid dehydrogenase type 2 gene (HSD17B2).
methodsWe included 158 incident cases of colorectal cancer and 563 randomly chosen control subjects from 28,345 women in the Women's Health Study aged 45 or older who provided blood samples and had no history of cancer or cardiovascular disease at baseline in 1993. All cases and controls were Caucasians of European descent. A total of 63 tagging and putative functional SNPs in the 5 genes were included for analysis. Unconditional logistic regression was used to estimate odds ratio (ORs) and 95% confidence intervals (CIs).
resultsThere was no association between variation in ESR1, ESR2, PGR, CYP19A1 and HSD17B2 and colorectal cancer risk after correction for multiple comparisons (p values after correction > or =0.25). There was also no association with any of the haplotypes examined (p > or = 0.15) and no evidence of joint effects of variants in the 5 genes (p > or = 0.51).
conclusionOur data offer insufficient support for an association between variation in ESR1, ESR2, PGR, CYP19A1, and HSD17B2 and risk for developing colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.